Šárka Fingerhutová

Šárka Fingerhutová

Auto-generated profile, based on publicly available information

Šárka Fingerhutová

Department of Pediatrics and Adolescent Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LKLianne Kearsley-Fleet
Lianne Kearsley-Fleet
MCMin-Lee Chang
Min-Lee Chang
SLSaskia Lawson-Tovey
Saskia Lawson-Tovey
RCRuth Costello
Ruth Costello
ŠFŠárka Fingerhutová
Šárka Fingerhutová
KHKimme L Hyrich
Kimme L Hyrich
Objectives Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19. Methods Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated. Results 607 CYP with RMDs <19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12). Conclusions This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised.

1 October 2026 in RMD Open
Verified
Journal Article
Open access
PDF file
AKAnna Kozáková
Anna Kozáková
Blanka StiburkovaBlanka Stiburkova
Blanka Stiburkova
JMJana Mašínová
Jana Mašínová
NHNikol Husáková
Nikol Husáková
PŠProkop Šeferna
Prokop Šeferna
ŠFŠárka Horáčková Fingerhutová
Šárka Horáčková Fingerhutová
Objective Syndrome of undifferentiated recurrent fever (SURF) is a new entity among non-hereditary periodic fever syndromes. Using a complex approach, we looked at clinical and laboratory profiles of the well-known syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) and patients with SURF during febrile and afebrile conditions searching for clinically meaningful differences.Methods Patients were prospectively enrolled and their symptoms recorded. Genetic analysis was part of the diagnostic process. Blood samples collected at specific times (febrile/afebrile) were compared with febrile and healthy controls for standard parameters (C-reactive protein (CRP), serum amyloid A, procalcitonin), S100A8/A9 and S100A12 proteins, and 48 mediators via Bio-Plex analysis, followed by ELISA confirmation.Results A total of 94 patients and 35 controls were recruited. Rash and diarrhoea, arthralgia, myalgia and abdominalgia were more frequent with longer fever duration in patients with SURF than with PFAPA, in whom significantly (p<0.001) better response to episodic prednisone was recorded. In febrile samples, inflammatory parameters or cytokines did not differ between groups apart from CRP being higher in periodic fever than controls. In an afebrile sample of patients with periodic fever, 11 proinflammatory cytokines were significantly higher than in healthy controls. Afebrile SURF and PFAPA differed significantly (p<0.05), with nine mediators higher and one lower in SURF.Conclusion Analysis of routine and experimental biomarkers revealed heterogeneous immune dysregulation. Elevation of several inflammatory mediators in afebrile sample of patients with periodic fever indicates subclinical inflammation with granulocyte colony-stimulating factor and interleukin-18 notably higher in SURF than in PFAPA. Our data provide new insights into the immune mechanisms of non-hereditary periodic fever syndromes and support further biomarker-driven research.

31 October 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ŠFŠárka Horáčková Fingerhutová
Šárka Horáčková Fingerhutová
PCPetr Chrastina
Petr Chrastina
EJEva Jančová
Eva Jančová
PKPetra Keslová
Petra Keslová
HMHana Malcová
Hana Malcová
PDPavla Dolezalova
Pavla Dolezalova
Background: Urinary mevalonic acid (MVA) analysis is a practical screening test for mevalonate kinase deficiency (MKD) in children with recurrent fever. We assessed its diagnostic accuracy, effects of sampling and preanalytical handling, and MVA dynamics during febrile and afebrile periods, considering the feasibility of urine collection. Methods: All urinary MVA analyses performed between January 2004 and July 2025 were reviewed retrospectively; prospective sampling experiments included 12 patients with genetically confirmed MKD. Diagnostic accuracy was assessed at sample and patient levels using only samples pooled from three consecutive urine portions (center protocol). Genetically confirmed cases were compared with clinically and/or genetically negative controls and, separately, with MVK-negative controls. Results: The dataset comprised 3,606 samples from 2,520 patients; 153/162 samples from the 22-patient descriptive cohort were MVA-positive. Seventy samples from 12 genetically confirmed cases were positive, and 308 samples from 306 clinical/genetic controls were negative, yielding observed sensitivity of 100% (95% CI 94.9–100.0) and specificity of 100% (95% CI 98.8–100.0). Genetic-reference and patient-level estimates were also 100%, although patient-level sensitivity, based on only 12 cases, had a wider confidence interval (95% CI 73.5–100.0). Because genetic testing was selective, the 100% estimates should be interpreted cautiously and within the context of this cohort. Handling affected concentrations in the one-patient experiment ( p = 0.008) without loss of detection, whereas collection type did not significantly affect febrile concentrations. MVA concentrations varied widely within and between patients, were higher during febrile than afebrile periods ( p < 0.001), and showed no consistent temporal pattern across serial samples. Conclusion: Standardized urinary MVA analysis using the three-portion protocol proved reliable and cost-effective screening for MKD in our cohort. Pooling three consecutive urine portions provides a practical alternative to 24-hour collection, particularly in children, with high observed diagnostic accuracy, though confirmation in larger cohorts with complete genetic verification is warranted. MVA concentration is higher during febrile than afebrile periods but varies substantially intra- and inter-individually. Appropriate preanalytical handling is important, particularly when concentrations are close to the detection limit. If clinical suspicion of MKD persists, MVK genetic testing should be performed despite a negative urinary MVA result.